NEWS

In this edition:

-  Global patterns and trends in breast cancer incidence and mortality
-  Sequential ADC use in HER2-low metastatic breast cancer
-  Imlunestrant ± abemaciclib in advanced breast cancer
-  Adjuvant atezolizumab for early triple-negative breast cancer
-  Nivolumab timing with neoadjuvant carboplatin and paclitaxel for triple-negative breast cancer
-  TILs and survival outcomes in HER2-positive breast cancer
-  Concurrent conditions and medications: impact on neoadjuvant chemotherapy response in breast cancer
-  TROP2 ADC for HER2-negative metastatic breast cancer with brain metastases
-  PROs with trastuzumab deruxtecan in hormone receptor-positive, HER2-low/-ultralow metastatic breast cancer
-  Pertuzumab retreatment for HER2-positive locally advanced/metastatic breast cancer